Idelalisib: targeting PI3Kδ in B-cell malignancies

Lancet Oncol. 2014 Mar;15(3):e108. doi: 10.1016/s1470-2045(14)70052-x.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Class I Phosphatidylinositol 3-Kinases
  • Clinical Trials as Topic
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Phosphoinositide-3 Kinase Inhibitors*
  • Purines / therapeutic use*
  • Quinazolinones / therapeutic use*

Substances

  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Purines
  • Quinazolinones
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CD protein, human
  • idelalisib